NervGen will meet with the FDA early next year to align on a regulatory path forward for NVG-291 in chronic spinal cord ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback